ONL Therapeutics Raises $3 Million in a Convertible Note to Advance ONL1204 into First-In-Human Clinical Study
22 août 2019 11h54 HE
|
ONL Therapeutics
ANN ARBOR, Mich., Aug. 22, 2019 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today...
ONL Therapeutics Raises $3 Million in a Convertible Note to Advance ONL1204 into First-In-Human Clinical Study
22 août 2019 07h00 HE
|
ONL Therapeutics
ANN ARBOR, Mich., Aug. 22, 2019 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today...
ONL Therapeutics Names Industry Veteran as CEO as Company Prepares for First in Human Clinical Trials
18 juin 2019 07h00 HE
|
ONL Therapeutics
ANN ARBOR, Mich., June 18, 2019 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving vision in a range of retinal diseases, today...
ONL Therapeutics Closes Series A Financing to Support Development of Novel Retinal Cell Protection Platform for Treatment of Ocular Diseases
17 mai 2017 08h05 HE
|
ONL Therapeutics
ANN ARBOR, MI--(Marketwired - May 17, 2017) - ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, today...
ONL Therapeutics Strengthens Leadership with Addition to Board of Directors and Expansion of Operations Team
28 mars 2017 08h05 HE
|
ONL Therapeutics
ANN ARBOR, MI--(Marketwired - Mar 28, 2017) - ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, today...
ONL Therapeutics Receives Nearly $1.0 Million Grant from National Eye Institute for Continued Advancement of ONL1204 Program
21 mars 2017 08h05 HE
|
ONL Therapeutics
ANN ARBOR, MI--(Marketwired - Mar 21, 2017) - ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, today announced...
ONL Therapeutics Receives Orphan Drug Designation for ONL1204 for Treatment of Retinal Detachment From FDA
11 févr. 2016 08h05 HE
|
ONL Therapeutics
ANN ARBOR, MI--(Marketwired - Feb 11, 2016) - ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, today announced...
ONL Therapeutics to Present at the 2015 Ophthalmology Innovation Summit at the American Academy of Ophthalmology Annual Meeting
29 oct. 2015 08h05 HE
|
ONL Therapeutics
ANN ARBOR, MI--(Marketwired - Oct 29, 2015) - ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, today announced...
ONL Therapeutics Announces Formation of Scientific Advisory Board
14 oct. 2015 08h05 HE
|
ONL Therapeutics
ANN ARBOR, MI--(Marketwired - Oct 14, 2015) - ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, today...
ONL Therapeutics Provides Update on Novel Photoreceptor Protection Platform for Retinal Diseases
15 juin 2015 08h00 HE
|
ONL Therapeutics
ANN ARBOR, MI--(Marketwired - Jun 15, 2015) - ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, today provided an...